DPP4 and type 2 diabetes mellitus: The publication of TECOS, another mega trial including 14 671 patients wastherefore long awaited.4Patients included had type 2 diabetes mellitus, were 50 years of age or more,and had an established cardiovascular disease and a baseline HbA1C of 6.5-8%.They were randomized to either the DPP4 inhibitor sitagliptin or to controltreatment.